David Frawley is Executive Vice President and Chief Commercial Officer at Sunovion Pharmaceuticals Inc., a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions. He joined the company in 2009 and is a member of the Sunovion Executive Leadership Team.
Since 2014, Mr. Frawley has led all sales, marketing, managed markets, and strategic commercial operations for the company’s psychiatry, neurology and respiratory franchises. In 2015, he was appointed Chief Commercial Officer.
Mr. Frawley led the US launch of Sunovion’s flagship product, Latuda® (lurasidone HCl) in 2011 and its subsequent commercialization in North America and Europe. He has overseen the growth of Aptiom® (eslicarbazepine acetate) and Brovana® (arformoterol tartrate), leads commercial planning efforts for late-stage development assets and is responsible for Sunovion subsidiaries in Canada and the UK, and the company’s expanding global business.
In 2015, Mr. Frawley accepted on behalf of Sunovion the Corporate Voice of Mental Health Award from the JED Foundation, a leading nonprofit organization working to protect the emotional health of teenagers and college students.
Mr. Frawley has more than 20 years of pharmaceutical industry expertise, primarily in the neuroscience field. Prior to joining Sunovion, he served as Assistant Vice President, Marketing, CNS at Forest Laboratories, Inc., where he directed all marketing activities for Lexapro® (escitalopram oxalate). Previously, he spent 10 years at Pfizer in the UK and US, leading the marketing of blockbuster CNS products including Geodon® (ziprasidone HCl), Zoloft® (sertraline HCl), and Viagra® (sildenafil citrate).
Mr. Frawley holds a Bachelor of Science degree in biochemistry from the University of Southampton and a Master of Business Administration from the Bradford University School of Management in the UK.